glp-1 receptor agonist pancreatitis risk meta-analysis Glucagon-Like Peptide-1 Agonists Use... : American Journal of Gastroenterology Glucagon-like Peptide-1 Receptor Agonist Use
Description
Maximum Weight Loss Survodutide Phase 2 data showed 18.7% weight loss at 46 weeks, exceeding pemvidutide's 15.6% at 48 weeks
ClinicalTrials.gov (2022)
Lower treatment burden While retatrutide shows significant promise, Eli Lilly is likely to disrupt the market more imminently and more substantially following the launch of orforglipron in early 2026
10,17 GLP-1 receptor stimulation in the arcuate nucleus also improves glycemic control independent of feeding behavior
